This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00113-08v1 52/9/3315    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Google Scholar Articles by Lodise, T. P. Articles by Stellrecht, K. PubMed PubMed Citation Articles by Lodise, T. P. Articles by Stellrecht, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2008, p. 3315-3320, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00113-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

Albany College of Pharmacy, Pharmacy Practice Department, Albany, New York,¹ Ordway Research Institute, Albany, New York,² Albany Medical Center Hospital, Department of Pathology and Laboratory Medicine, Albany, New York,³ Albany Medical Center Hospital, Department of Epidemiology, Albany, New York,⁴ Albany Medical Center Hospital, Department of Pharmacy, Albany, New York⁵

Received 25 January 2008/ Returned for modification 20 March 2008/ Accepted 23 June 2008

There is growing concern that vancomycin has diminished activity for methicillin-resistant Staphylococcus aureus (MRSA) infections, with vancomycin MICs at the high end of the CLSI susceptibility range. Despite this growing concern, there are limited clinical data to support this notion. To better elucidate this, a retrospective cohort study was conducted among patients with MRSA bloodstream infections who were treated with vancomycin between January 2005 and May 2007. The inclusion criteria were as follows: at least 18 years old, nonneutropenic, with an MRSA culture that met the CDC criteria for bloodstream infection, had received vancomycin therapy within 48 h of the index blood culture, and survived >24 h after vancomycin administration. Failure was defined as 30-day mortality, bacteremia 10 days on vancomycin therapy, or a recurrence of MRSA bacteremia within 60 days of vancomycin discontinuation. Classification and regression tree (CART) analysis identified the vancomycin MIC breakpoint associated with an increased probability of failure. During the study period, 92 patients met the inclusion criteria. The vancomycin MIC breakpoint derived by CART analysis was 1.5 mg/liter. The 66 patients with vancomycin MICs of 1.5 mg/liter had a 2.4-fold increase in failure compared to patients with MICs of 1.0 mg/liter (36.4% and 15.4%, respectively; P = 0.049). In the Poisson regression, a vancomycin MIC of 1.5 mg/liter was independently associated with failure (adjusted risk ratio, 2.6; 95% confidence interval, 1.3 to 5.4; P = 0.01). These data strongly suggest that patients with MRSA bloodstream infections with vancomycin MICs of 1.5 mg/liter respond poorly to vancomycin. Alternative anti-MRSA therapies should be considered for these patients.

Published ahead of print on 30 June 2008.

This article has been cited by other articles:

• Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R. Jr., Craig, W., Billeter, M., Dalovisio, J. R., Levine, D. P. (2009). Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82-98 [Full Text]  
• Rehm, S. J., Boucher, H., Levine, D., Campion, M., Eisenstein, B. I., Vigliani, G. A., Corey, G.R., Abrutyn, E. (2008). Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 62: 1413-1421 [Abstract] [Full Text]